Quality ImprovementAppropriations LanguageSITC Policy Committees

SITC Statement on NIH Indirect Costs

SITC released a statement addressing their concerns for the recent announcement from the National Institutes of Health (NIH)  that will cut billions of dollars in indirect costs for current and future grants to research institutions across the U.S.

SITC Statement on Major Staff Reductions at the Department of Health and Human Services

SITC is deeply concerned that these cuts are already resulting in profound and detrimental impact on the United States' research and development ecosystem.

Quality Improvement

The development and stewardship of Immunotherapy specific quality measures is aimed at directly impacting day to day patient care, with the goal of improving outcomes and serving the field.

Through multiple quality initiatives – including the identification of measure concepts – the development of quality measures and the stewardship of measures through CMS and other quality programs, SITC strives to make sure that each patient receives the highest quality of care, regardless of where they receive immunotherapy.

Published SITC Quality Measure Concepts

Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit

LEARN MORE

Current SITC MIPS Measures

Positive PD-L1 Biomarker Expression Test Result Prior to First-Line Immune Checkpoint Inhibitor Therapy

Quality ID #490: Appropriate Intervention of Immune-Related Diarrhea and/or Colitis in Patients Treated with Immune Checkpoint Inhibitors

LEARN MORE

Advocacy News

SITC Hosts "Using Spatial Biology to Monitor Tumor Immune Interactions: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted yesterday
On November, 13, 2025, the Society for Immunotherapy of Cancer (SITC) in partnership with the National Cancer Institute (NCI) held the ninth computational immuno-oncology webinar of series 5. This webinar ...

Thank You to Our SITC Advocacy Day Volunteers

By SITC Advocacy posted 14 days ago
On Nov. 5, 2025, dedicated volunteers from across the country joined us in Washington, DC, bringing their passion, expertise, and personal stories to the heart of our nation’s capital. Together, they ...

SITC Hosts "Liquid Biopsy Approaches for Cancer Diagnosis and Monitoring: Computational Science in Immuno-oncology" Webinar

By SITC Advocacy posted 29 days ago
On October 16, 2025, the Society for Immunotherapy of Cancer (SITC) in partnership with the National Cancer Institute (NCI) held the eighth computational immuno-oncology webinar of series 5. In this webinar, ...

Appropriations Language

SITC annually drafts report language for consideration by the U.S. House of Representatives and Senate Appropriations Committees to be incorporated into appropriations bills.

Incorporation of report language helps advocate for funding of federal agencies supporting cancer immunotherapy research and regulation, including the U.S. Food and Drug Administration (FDA) and National Cancer Institute (NCI).

Continue reading below to view past language submitted on behalf of the society to the FDA and NCI.

Past NCI Appropriations Language

Past FDA Appropriations Language

SITC Policy Committees

2 total

Public Policy and Advocacy Committee  

The Policy and Advocacy Committee reviews and analyzes immunotherapy and oncology related policy issues to advise the Board of Directors on the broad policy, advocacy, regulatory and value priorities of the society. The committee serves at the pleasure of the Board of Directors, representing the society when requested and supporting the development of talking points for the board when asked. The committee works with relevant subcommittees to achieve its purpose.

  last person joined 10 months ago

View Only

Quality Committee  

The Quality Committee assists the Policy and Advocacy Committee in the articulation, development and dissemination of a value framework for cancer immunotherapy and areas focused on patient access and delivery of care, data sharing and research, quality, and other activities under the Center for Medicare and Medicaid Services (CMS), including coverage, reimbursement and engagement with private payers.

  last person joined 4 years ago

View Only